All In Biotech

Drug Trial Radar · NCT04906395

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Jul 1, 2021

Primary completion

Jan 30, 2027

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Tolmar Inc.Industry
Sponsor type
Industry
First posted
May 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The study will also aim to assess the safety of TOL2506 in men with HR+, HER2-negative breast cancer. The Screening Period will be conducted in two parts: 1) an abbreviated, initial screening where premenopausal status will be determined prior to neoadjuvant or adjuvant chemotherapy (if planned) and 2) the full screening assessment conducted after neoadjuvant or adjuvant chemotherapy (or for subjects who enter the study without having received chemotherapy). Following the Screening Period, eligible subjects will enter into the 48 week Treatment Period in 1 of 2 groups: those who will receive tamoxifen concurrently with TOL2506 or those who will initiate therapy with an AI (letrozole, anastrozole, or exemestane) beginning 6 weeks after the first administration of TOL2506, upon confirmation that estradiol (E2) levels of \< 20 pg/mL (testosterone levels \< 50 ng/dL in males) have been achieved. After Week 12, subjects will be allowed to switch from receiving an AI to receiving tamoxifen or from tamoxifen to AI at the discretion of the Investigator. However, a switch is not permitted 28 days prior to a dosing visit (eg, Week 24, 36, and 48 where a pre-dose blood sample for PK and PD analysis will be drawn). At the end of the Treatment Period, upon completion of the End of Study Visit (Visit 9, Week 48) subjects may be eligible to participate in a Safety Extension Study under a separate Protocol.

Conditions

  • Breast Cancer

Interventions

  • TOL2506Drug

    Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.

  • TamoxifenDrug

    20 mg once daily or 10 mg 2 times daily - either tablet or solution

  • Letrozole TabletsDrug

    One 2.5 mg tablet taken orally once daily

  • Anastrozole TabletsDrug

    One 1 mg tablet taken orally once daily

  • Exemestane TabletsDrug

    One 25 mg tablet taken orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Suppression of ovarian functionTime frame: 6 weeks after the first administration of TOL2506

Locations

59 sites in 7 countries. Site status is shown where the registry gives one.

  • Marin Cancer Care, Inc

    Greenbrae, California

  • Cypress Hematology and Oncology

    Parker, Colorado

  • Mount Sinai Hospital

    Chicago, Illinois

  • Baptist Health Louisville

    Louisville, Kentucky

  • Maryland Oncology Hematology, P.A.

    Glenn Dale, Maryland

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Montefiore - Einstein Center for Cancer Care at Montefiore Medical Park

    The Bronx, New York

  • Oncology Hematology Care Clinical Trials

    Cincinnati, Ohio

  • Lankenau Medical Center

    Wynnewood, Pennsylvania

  • Tennessee Oncology, PLLC

    Chattanooga, Tennessee

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Texas Oncology-Austin

    Austin, Texas

  • Texas Oncology- Dallas Presbyterian Hospital

    Dallas, Texas

  • Texas Oncology- San Antonio

    New Braunfels, Texas

  • Texas Oncology- Northeast Texas

    Tyler, Texas

  • Texas Oncology- Deke Slayton Cancer Center

    Webster, Texas

  • Seattle Cancer Center Alliance

    Seattle, Washington

  • Hospital Aleman

    Buenos Aires, Argentina

  • Fundacion CENIT

    CABA, Argentina

  • Sanatorio Allende- Sede Nueva Cordoba

    Córdoba, Argentina

  • Hospital Britanico de Buenos Aires

    Buenos Aires, Buenos Aires F.D., Argentina

  • Instituto Oncologico de Cordoba (IONC)

    Córdoba, Córdoba Province, Argentina

  • Centro Privado de RMI Rio Cuarto

    Río Cuarto, Córdoba Province, Argentina

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Santa Fe Province, Argentina

  • Hospital Provincial del Centenario

    Rosario, Santa Fe Province, Argentina

  • Irmamandade de Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Brazil

  • Instituto de Educacao, Pesquisa e Gestao em Saude

    Rio de Janeiro, Brazil

  • Oncocentro Servicos Medicos e Hospitalares Ltda

    Fortaleza, Ceará, Brazil

  • Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazil

  • Hospital Sao Rafael

    Salvador, Estado de Bahia, Brazil

  • Hospital Araujo Jorge

    Goiânia, Goiás, Brazil

  • Onconeo

    Campo Grande, Mato Grosso do Sul, Brazil

  • Hospital do Cancer de Londrina

    Londrina, Paraná, Brazil

  • Uniao Brasileira de Educacao e Assistencia

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Amor Amazonia

    Porto Velho, Rondônia, Brazil

  • Fundacao Pio XII

    Barretos, São Paulo, Brazil

  • Centro de Estudos e Pesquisas de Hematologia e Oncologia da Faculdade de Medicina do ABC

    Santo André, São Paulo, Brazil

  • Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria

    São Paulo, São Paulo, Brazil

  • Sunnybrook Odette Cancer Centre Clinical Research Program

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.